CRISPR Therapeutics (NASDAQ:CRSP) Given “Market Outperform” Rating at JMP Securities

JMP Securities reissued their market outperform rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research note issued to investors on Friday,Benzinga reports. JMP Securities currently has a $86.00 target price on the stock.

A number of other analysts have also recently weighed in on CRSP. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Wednesday, December 11th. Barclays dropped their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Chardan Capital reiterated a “buy” rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $77.93.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $40.72 on Friday. CRISPR Therapeutics has a 12 month low of $39.41 and a 12 month high of $91.10. The company has a market cap of $3.48 billion, a price-to-earnings ratio of -14.39 and a beta of 1.62. The stock’s 50-day moving average is $48.45 and its 200-day moving average is $50.78.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same period in the previous year, the company posted ($1.41) earnings per share. Research analysts anticipate that CRISPR Therapeutics will post -5.13 EPS for the current year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Samarth Kulkarni sold 30,000 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the sale, the chief executive officer now directly owns 196,540 shares in the company, valued at $10,931,554.80. This trade represents a 13.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,382 shares of company stock valued at $2,744,179 over the last three months. 4.10% of the stock is owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Larson Financial Group LLC boosted its position in CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares during the period. Itau Unibanco Holding S.A. acquired a new position in shares of CRISPR Therapeutics during the second quarter valued at $35,000. Denver PWM LLC bought a new position in shares of CRISPR Therapeutics during the second quarter worth about $45,000. National Bank of Canada FI increased its holdings in shares of CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after acquiring an additional 220 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in CRISPR Therapeutics in the 3rd quarter valued at about $40,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.